David A. Lawrence

22.6k total citations · 7 hit papers
282 papers, 17.4k citations indexed

About

David A. Lawrence is a scholar working on Molecular Biology, Immunology and Health, Toxicology and Mutagenesis. According to data from OpenAlex, David A. Lawrence has authored 282 papers receiving a total of 17.4k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Molecular Biology, 80 papers in Immunology and 42 papers in Health, Toxicology and Mutagenesis. Recurrent topics in David A. Lawrence's work include Heavy Metal Exposure and Toxicity (33 papers), Immune Response and Inflammation (24 papers) and Immunotoxicology and immune responses (21 papers). David A. Lawrence is often cited by papers focused on Heavy Metal Exposure and Toxicity (33 papers), Immune Response and Inflammation (24 papers) and Immunotoxicology and immune responses (21 papers). David A. Lawrence collaborates with scholars based in United States, France and United Kingdom. David A. Lawrence's co-authors include Avi Ashkenazi, Pierre Jullien, Scot A. Marsters, Frank Kischkel, Peter Schow, Robert Pitti, Sharon Fong, Ralph Schwall, Yong Heo and Avi Ashkenazi and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

David A. Lawrence

277 papers receiving 16.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and antitumor activity of recombinant soluble Apo2 ligand

1999 1.9k citations Avi Ashkenazi, Sharon Fong et al. profile →
Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5

2000 816 citations David A. Lawrence, Peter Schow et al. profile →
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer

1998 645 citations Scot A. Marsters, David A. Lawrence et al. profile →
Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling

2009 502 citations David A. Lawrence, Avi Ashkenazi et al. profile →
Deterministic hydrodynamics: Taking blood apart

2006 495 citations David A. Lawrence et al. profile →
Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis

2014 447 citations Min Lu, David A. Lawrence et al. Science profile →
Dietary fish oil and olive oil supplementation in patients with Rheumatoid Arthritis clinical and immunologic effects

1990 435 citations David A. Lawrence et al. profile →

Peers

Countries citing papers authored by David A. Lawrence

Since Specialization

Citations

This map shows the geographic impact of David A. Lawrence's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Lawrence with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Lawrence more than expected).

Fields of papers citing papers by David A. Lawrence

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Lawrence. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Lawrence. The network helps show where David A. Lawrence may publish in the future.

Co-authorship network of co-authors of David A. Lawrence

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Lawrence. A scholar is included among the top collaborators of David A. Lawrence based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Lawrence. David A. Lawrence is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration 2025 ·Eye ·Carl D. Regillo, Peter K. Kaiser, Peter J. Kertes, Mark C. Gillies, (unknown), David A. Lawrence, Frank G. Holz	0
2	TALON Phase IIIb Study: 32-Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age-Related Macular Degeneration 2025 ·Ophthalmology Retina ·Carl D. Regillo, Peter K. Kaiser, Peter J. Kertes, Mark C. Gillies, (unknown), (unknown), (unknown), David A. Lawrence, Frank G. Holz	2
3	Inflammatory and Autoimmune Aspects of Multisystem Inflammatory Syndrome in Children (MIS-C): A Prospective Cohort Study 2024 ·Viruses ·David A. Lawrence, (unknown), Tapan Kumar Mondal, Kyle Carson, William T. Lee, (unknown), Katherine W. Herbst, Ian C. Michelow, Michael Brimacombe, Juan C. Salazar, (unknown)	3
4	Climate Stressors and Physiological Dysregulations: Mechanistic Connections to Pathologies 2023 ·International Journal of Environmental Research and Public Health ·(unknown), David A. Lawrence	5
5	Associations of SARS-CoV-2 antibodies with birth outcomes: Results from three urban birth cohorts in the NIH environmental influences on child health outcomes program 2023 ·PLoS ONE ·Leonardo Trasande, Sarah S. Comstock, Julie B. Herbstman, Amy Margolis, Garry Alcedo, Yelena Afanasyeva, (unknown), William T. Lee, David A. Lawrence, (unknown)	0
6	Development of a biomarker signature using grating-coupled fluorescence plasmonic microarray for diagnosis of MIS-C 2023 ·Frontiers in Bioengineering and Biotechnology ·(unknown), (unknown), Katherine W. Herbst, (unknown), (unknown), (unknown), Joerg Graf, (unknown), David A. Lawrence, William T. Lee, Kyle Carson, Justin D. Radolf, Juan Carlos Salazar, Michael A. Lynes, (unknown)	3
7	Antigen-derived peptides engage the ER stress sensor IRE1α to curb dendritic cell cross-presentation 2022 ·The Journal of Cell Biology ·Ofer Guttman, Adrien Le Thomas, Scot A. Marsters, David A. Lawrence, (unknown), Iratxe Zuazo-Gaztelu, Jonathan M. Harnoss, Simone M. Haag, Aditya Murthy, Geraldine Strasser, Zora Modrušan, Thomas D. Wu, Ira Mellman, Avi Ashkenazi	28
8	Decoding non-canonical mRNA decay by the endoplasmic-reticulum stress sensor IRE1α 2021 ·Nature Communications ·Adrien Le Thomas, Elena Ferri, Scot A. Marsters, Jonathan M. Harnoss, David A. Lawrence, Iratxe Zuazo-Gaztelu, Zora Modrušan, Sara M. Chan, Margaret Solon, Cécile Chalouni, Weihan Li, Hartmut Koeppen, Joachim Rudolph, Weiru Wang, Thomas D. Wu, Peter Walter, Avi Ashkenazi	41
9	Conception by fertility treatment and offspring deoxyribonucleic acid methylation 2021 ·Fertility and Sterility ·Edwina Yeung, Pauline Mendola, Rajeshwari Sundaram, (unknown), Weihua Guan, Michael Y. Tsai, Sonia L. Robinson, Judy E. Stern, Akhgar Ghassabian, David A. Lawrence, Thomas G. O’Connor, James H. Segars, Robert E. Gore‐Langton, Erin M. Bell	20
10	Eliciting parental support for the use of newborn blood spots for pediatric research 2016 ·BMC Medical Research Methodology ·Edwina Yeung, Germaine M. Buck Louis, David A. Lawrence, Kurunthachalam Kannan, Alexander C. McLain, Michele Caggana, Charlotte M. Druschel, Erin M. Bell	28
11	Prenatal exposures and exposomics of asthma 2015 ·AIMS environmental science ·Hyunok Choi, (unknown), David A. Lawrence	4
12	Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis breakdown → 2014 ·Science ·Min Lu, David A. Lawrence, Scot A. Marsters, Diego Acosta‐Alvear, Philipp Kimmig, Aaron S. Mendez, Adrienne W. Paton, James C. Paton, Peter Walter, Avi Ashkenazi	447
13	Effects of echinocandins on cytokine/chemokine production by human monocytes activated by infection with Candida glabrata or by lipopolysaccharide 2011 ·Diagnostic Microbiology and Infectious Disease ·Aldona L. Baltch, David A. Lawrence, William J. Ritz, (unknown), Lawrence H. Bopp, Poul Michelsen, Cynthia J. Carlyn, Raymond P. Smith	8
14	β1-Adrenergic Receptors on Immune Cells Impair Innate Defenses against Listeria 2007 ·The Journal of Immunology ·Rebecca T. Emeny, Donghong Gao, David A. Lawrence	31
15	Selective Knockdown of the Long Variant of Cellular FLICE Inhibitory Protein Augments Death Receptor-mediated Caspase-8 Activation and Apoptosis 2005 ·Journal of Biological Chemistry ·(unknown), David A. Lawrence, Avi Ashkenazi	125
16	Bio-impedance Sensing Device (BISD) for Detection of Human CD4 + Cells 2004 ·TechConnect Briefs ·M. Isaacson, David A. Lawrence, Nikhil Mishra, (unknown), (unknown), Donald H. Szarowski, James N. Turner, (unknown)	3
17	Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax 2002 ·Nature Medicine ·Heidi Leblanc, David A. Lawrence, Eugene Varfolomeev, Klára Tótpál, John Morlan, Peter Schow, Sharon Fong, Ralph Schwall, Dominick Sinicropi, Avi Ashkenazi	431
18	Role of Endogenous Cytokines in Endotoxin- and Interleukin-1-Induced Pulmonary Inflammatory Response and Oxygen Tolerance 1995 ·American Journal of Respiratory Cell and Molecular Biology ·(unknown), Jack E. White, Philip D. Lumb, David A. Lawrence, Min‐Fu Tsan	23
19	[Modulation, by transforming growth factor beta (TGF beta), of the mitogenic effect of fibroblast growth factor (FGF) on rat oligodendrocytes in culture]. 1989 ·PubMed ·F. Besnard, David A. Lawrence, M. Sensenbrenner, G. Labourdette	5
20	2,4-DINITROPHENYL RECEPTORS ON MOUSE THYMUS AND SPLEEN CELLS 1973 ·The Journal of Experimental Medicine ·David A. Lawrence, Hans L. Spiegelberg, William O. Weigle	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact